n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with mocetinostat in 2 studies
Studies (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine) | Trials (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine) | Recent Studies (post-2010) (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine) | Studies (mocetinostat) | Trials (mocetinostat) | Recent Studies (post-2010) (mocetinostat) |
---|---|---|---|---|---|
214 | 5 | 58 | 21,735 | 390 | 8,606 |
Protein | Taxonomy | n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine (IC50) | mocetinostat (IC50) |
---|---|---|---|
Histone deacetylase 3 | Homo sapiens (human) | 0.7851 | |
Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.022 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.57 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 0.102 | |
Cytochrome P450 2C19 | Homo sapiens (human) | 0.102 | |
Histone deacetylase 4 | Homo sapiens (human) | 0.5717 | |
Histone deacetylase 1 | Homo sapiens (human) | 0.3433 | |
Histone deacetylase 7 | Homo sapiens (human) | 0.6725 | |
Histone deacetylase 2 | Homo sapiens (human) | 0.3537 | |
Histone deacetylase 11 | Homo sapiens (human) | 0.6386 | |
Histone deacetylase 8 | Homo sapiens (human) | 0.6725 | |
Histone deacetylase 6 | Homo sapiens (human) | 0.5717 | |
Histone deacetylase 5 | Homo sapiens (human) | 0.6725 | |
Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.045 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Haskó, G; Mabley, J; Marton, A; Pacher, P; Salzman, A; Soriano, F; Szabó, C; Wallace, R | 1 |
Gazoni, LM; Kron, IL; Laubach, VE; Linden, J; Unger, EB; Walters, DM | 1 |
2 other study(ies) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and mocetinostat
Article | Year |
---|---|
The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis.
Topics: Adenosine; Animals; Chemokine CCL4; Chemokine CXCL2; Chemokines; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Dose-Response Relationship, Drug; Gastrointestinal Hemorrhage; Interleukin-1; Interleukin-12; Interleukin-6; Macrophage Inflammatory Proteins; Male; Malondialdehyde; Mice; Mice, Inbred BALB C; Mice, Knockout; Peroxidase; Purinergic P1 Receptor Agonists; Receptor, Adenosine A3; Rectal Diseases; Weight Loss | 2003 |
Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Animals; Blood Pressure; Disease Models, Animal; In Vitro Techniques; Lung; Lung Compliance; Lung Diseases; Perfusion; Peroxidase; Piperidines; Protective Agents; Pulmonary Artery; Pulmonary Edema; Rabbits; Receptor, Adenosine A1; Receptor, Adenosine A2A; Receptor, Adenosine A3; Reperfusion Injury; Tumor Necrosis Factor-alpha | 2010 |